Alcohol and hospital admissions for injury and alcohol poisoning in West Sussex– a second order Monte Carlo simulation Ross Maconachie Public Health WSCC.

Slides:



Advertisements
Similar presentations
Health Economics for Prescribers
Advertisements

Markov Models: Overview Gerald F. Kominski, Ph.D. Professor, Department of Health Services.
Exploring uncertainty in cost effectiveness analysis NICE International and HITAP copyright © 2013 Francis Ruiz NICE International (acknowledgements to:
Statistical Issues in Research Planning and Evaluation
Decision Analysis. What is decision analysis? Based on expected utility theory Based on expected utility theory Used in conditions of uncertainty Used.
Introduction to Medical Decision Making and Decision Analysis
What role should probabilistic sensitivity analysis play in SMC decision making? Andrew Briggs, DPhil University of Oxford.
Engineering Economic Analysis Canadian Edition
1 Cost-effectiveness analysis using Markov modeling Rahul Ganguly Ph.D. November 25 th, 2006 BITS, Pilani.
The role of economic modelling – a brief introduction Francis Ruiz NICE International © NICE 2014.
Introduction to decision modelling Andrew Sutton.
Planning under Uncertainty
4.1 Option Prices: numerical approach Lecture Pricing: 1.Binomial Trees.
The Importance of Decision Analytic Modelling in Evaluating Health Care Interventions Mark Sculpher Professor of Health Economics Centre for Health Economics.
Journal Club Alcohol and Health: Current Evidence March-April 2006.
Results 2 (cont’d) c) Long term observational data on the duration of effective response Observational data on n=50 has EVSI = £867 d) Collect data on.
C82MCP Diploma Statistics School of Psychology University of Nottingham 1 Overview Parameters and Statistics Probabilities The Binomial Probability Test.
Health care decision making Dr. Giampiero Favato presented at the University Program in Health Economics Ragusa, June 2008.
Independent Sample T-test Often used with experimental designs N subjects are randomly assigned to two groups (Control * Treatment). After treatment, the.
Using ranking and DCE data to value health states on the QALY scale using conventional and Bayesian methods Theresa Cain.
Decision Analysis as a Basis for Estimating Cost- Effectiveness: The Experience of the National Institute for Health and Clinical Excellence in the UK.
Health Economics & Policy 3 rd Edition James W. Henderson Chapter 4 Economic Evaluation in Health Care.
Probability and Probability Distributions
1 Cost-effectiveness of improving medical services in low-resource settings Edward Broughton, PhD, MPH, PT University Research Co. May 21, 2014
Multiple Choice Questions for discussion
University of Minnesota Medical Technology Evaluation and Market Research Course: MILI/PUBH 6589 Spring Semester, 2012 Stephen T. Parente, Ph.D. Carlson.
Evidence Evaluation & Methods Workgroup: Developing a Decision Analysis Model Lisa A. Prosser, PhD, MS September 23, 2011.
EVIDENCE BASED MEDICINE Health economics Ross Lawrenson.
Economic evaluation of health programmes Department of Epidemiology, Biostatistics and Occupational Health Class no. 17: Economic Evaluation using Decision.
Comparing Two Population Means
Estimating Outcomes in Decision Analysis Brian Harris MPP Candidate Goldman School of Public Policy University of California, Berkeley.
St5219: Bayesian hierarchical modelling lecture 2.1.
Using Probability and Discrete Probability Distributions
Engineering Economic Analysis Canadian Edition
Dynamic Lines. Dynamic analysis n Health of people and activity of medical establishments change in time. n Studying of dynamics of the phenomena is very.
Basic Economic Analysis David Epstein, Centre for Health Economics, York.
Cost-Effectiveness and Cost-Benefit Analysis N287E Spring 2006 Joanne Spetz 31 May 2006.
Validation / citations. Validation u Expert review of model structure u Expert review of basic code implementation u Reproduce original inputs u Correctly.
Economic evaluation of health programmes Department of Epidemiology, Biostatistics and Occupational Health Class no. 19: Economic Evaluation using Patient-Level.
Economic evaluation of health programmes Department of Epidemiology, Biostatistics and Occupational Health Class no. 23: Nov 17, 2008.
Relative Values. Statistical Terms n Mean:  the average of the data  sensitive to outlying data n Median:  the middle of the data  not sensitive to.
POSC 202A: Lecture 4 Probability. We begin with the basics of probability and then move on to expected value. Understanding probability is important because.
Introduction to Probabilistic Analysis Introduction to Probabilistic Analysis The third phase of the cycle incorporates uncertainty into the analysis.
Conceptual Addition of Adherence to a Markov Model In the adherence-naïve model, medication adherence and associated effectiveness assumed to be trial.
EBM --- Journal Reading Presenter :葉麗雯 Date : 2005/10/27.
Summary of Previous Lecture Understand why ranking project proposals on the basis of IRR, NPV, and PI methods “may” lead to conflicts in ranking. Describe.
Introduction to decision analysis modeling Alice Zwerling, Postdoctoral fellow, JHSPH McGill TB Research Methods Course July 7, 2015.
Hypothesis test flow chart
HYPOTHESIS TESTING FOR DIFFERENCES BETWEEN MEANS AND BETWEEN PROPORTIONS.
A Cost-Effectiveness Analysis of Maternal Genotyping to Guide Treatment in Postnatal Patients.
Review Design of experiments, histograms, average and standard deviation, normal approximation, measurement error, and probability.
1 Edward Broughton, PhD., MPH Director of Research and Evaluation, USAID Health Care Improvement Project, University Research Co., LLC
Economics of Complementary and Integrative Medicine: Where Do We Go From Here? Patricia M. Herman, ND, PhD, RAND Corporation IM4US Boston August 8, 2014.
Date of download: 6/26/2016 From: Cost-Effectiveness of Adding Cardiac Resynchronization Therapy to an Implantable Cardioverter- Defibrillator Among Patients.
The University of Sheffield Extrapolation methods:
Introduction Out-of-hospital cardiac arrest (OHCA) is the sudden cessation of the heart in an out of hospital setting. In the United States, the incidence.
Cost effectiveness Analysis: Valuing Health; Valuing Research!
From: Cost-Effectiveness of Genotype-Guided and Dual Antiplatelet Therapies in Acute Coronary Syndrome Ann Intern Med. 2014;160(4): doi: /M
For a copy of the poster:
Relative Values.
Markov model structure
Mechanical thrombectomy
Background & Objectives
From: Tipping the Balance of Benefits and Harms to Favor Screening Mammography Starting at Age 40 YearsA Comparative Modeling Study of Risk Ann Intern.
Cost-effectiveness of intelligent Liver Function test(iLFT) for investigation of patients with abnormal liver function tests Rezaei Hemami M1, Boyd K.
Health care decision making
A comparison of open and endovascular revascularization for chronic mesenteric ischemia in a clinical decision model  Wouter Hogendoorn, MD, M.G. Myriam.
Erythropoietic Growth Factors for Treatment-Induced Anemia in Hepatitis C: A Cost- Effectiveness Analysis  Brennan M.R. Spiegel, Kristina Chen, Chiun–Fang.
Decision analysis to define the optimal management of athletes with anomalous aortic origin of a coronary artery  Carlos M. Mery, MD, MPH, Keila N. Lopez,
Presentation transcript:

Alcohol and hospital admissions for injury and alcohol poisoning in West Sussex– a second order Monte Carlo simulation Ross Maconachie Public Health WSCC

Cost Effectiveness and ICERS Incremental economic evaluations are designed to answer the question: “What is the difference in costs and the difference in consequences of option A compared to option B?” Incremental Cost Effectiveness Ratio (ICER) is ICER = ∆C/∆E N S E W Threshold ICER Dominates Dominated CE Not CE NW quadrant is never cost effective SE quadrant is always cost effective NE depends on willingness to pay SW depends on willingness to accept

Decision Trees Used for short term costs and outcomes modelling, e.g. acute disease Probability of each branch of the tree is calculated from literature then costs and outcomes are “rolled back” to calculate difference in arms. Difference between the arms is used to calculate an Incremental Cost Effectiveness Ratio

Calculating Costs and Outcomes of Different Options Using a Decision Tree Rules Probabilities branching from each node must add up to 1 Costs and outcomes are placed at each node The probability of a given branch of a tree occurring is the product of all the probabilities along the branch

Exercise Decision to give Warfarin or not for patients with cardiomyopathy Patients have a probability to have an embolism, which is significantly reduced if they take warfarin but the drug produces a probability to have a bleeding incident Use the data below to calculate the difference in costs and QALYs between the warfarin and no warfarin arms of the trial Base case parameters ProbabilitiesP no warfarin probability of embolism0.09 warfarin probability of embolism0.017 warfarin probability of bleeding incident0.045 OutcomesQALY QALY for no warfarin embolism2.3 QALY for no warfarin no embolism4.5 QALY for warfarin embolism bleed1.8 QALY for warfarin no embolism bleed4 QALY for warfarin embolism no bleed2.3 QALY for warfarin no embolism no bleed4.5 NHS costs no warfarin no embolism100 no warfarin embolism1000 warfarin no embolism350 warfarin embolism1350 Bleed20

No embolism No warfarin Embolism Cardiomyopathy No bleed No embolism Bleed Warfarin No bleed Embolism Bleed Results ICER = (367.9 – 181) / (4.44 – 4.302) = £1,305 per QALY

Markov Models Appropriate when there is reoccurrence Can describe longer time horizons e.g. Disease process that evolves over time The progression of a chronic disease Estimate long term costs and life years gained

Markov Models Markov (health) States Should be mutually exclusive and exhaustive Markov cycle length: a fixed period of time e.g. one month/one year are common Transition Probabilities Transition from one state into another at the end of a single cycle Fixed transition probabilities out of each state adding up to 1 Markov Rewards Values assigned to each health state that represent the cost and utility of spending one cycle in that state (e.g. assign a cost for spending one unit of time in a ‘treatment’ state

Markov Models Notice the probability of staying dead once you enter the ‘dead’ state is 1.0!

Markov Models The example here is Motor Neurone Disease, a progressive neurodegenerative disorder

Markov Assumption For any individual, the probability of transition from any state to and state is independent of previous history Once in a health state, no memory of previous health state or timing E.g. it makes no difference a mild person if they have been moderate or severe before (or, indeed, how long they were ‘severe’ for) There are ways to relax this assumption but we won’t cover them here

Not all patients are the same! Monte Carlo Simulation (A bit more complex) Track the path of individual patients by 1 st order Monte Carlo:- Generating a random number to determine starting health state Continue generating random numbers to determine which health states the patient transitions to cycle to cycle Record costs and outcomes for every cycle in the stated time horizon and repeat 10,000 times to obtain means and distributions of results Probabilistic Sensitivity Analysis (Second Order Monte Carlo):- Randomly (based on an appropriate distribution) vary all transition probabilities, costs and outcomes in the model simultaneously and repeatedly resample Deterministic Sensitivity Analysis Vary this data to pre-specified extremes or specific scenarios

Alcohol model – Barbosa et al 2010 Assess the effect of a medium term intervention on LTCs associated with alcohol use Does not include admissions due to external causes (injuries) or alcohol poisoning Probability of death in any state is state-modified age/sex mortality rate

West Sussex Model Steps Rebuild Barbosa model structure as the “control group” Add intervention to the model structure – in this case patients have the chance to refer themselves to psychosocial counselling every time they transition into a state of harmful drinking Obtain new probabilities and cost data from published sources

Data in the model Treatment referral probability calculated from prevalence of harmful users vs. numbers referring to treatment per year (about 3.5%) Costs of “being an alcoholic” calculated by obtaining total costs from SUS database, applying harmful user attributable from literature estimate divided by number harmful users for male and female Costs of treatment were taken as the average attendances at the average cost (incl training etc.) Assumptions Men are double as likely to be high risk drinkers as women but total prevalence is still roughly 6.75% (GHS 2009) Men have 3% below the mean abstinence rate and women 3% above (GHS 2009) Unsuccessful treatment completions are transferred equally into hazardous and harmful (lack of data) Treatment success is equal between males and females (no data) Transition probabilities between states (other than treatment referral) do not differ between men and women (as assumed in Barbosa et al. 2010) Probability of dying while in treatment is equal to Ex-harmful (lack of data) Simpson's rule is applied to utilities because they occur incrementally through the cycles but as costs are attached to discrete events simpsons rule has not been applied

The Results TypeOptionCost (£)QALYsInc CostInc QALYs ICER (£/QALY) Deterministic Alc Male/Alc Male Treat£ £ £3, Deterministic Alc Female/Alc Female Treat£ £ £4, When only costs of hospital admissions for injuries and poisoning are included, the treatment costs £3k per QALY for men and £5k per QALY for women. The difference is due to the cost of men being in ‘harmful’ states being higher, meaning that the intervention is more valuable.

Second Order Monte Carlo Remember – not all patients will be the same and there is uncertainty around most of our parameters (modelled using standard errors). Probability distributions are constructed from the mean and standard error of each parameter. For example, attendances at counselling had a mean of 15 and a standard deviation 4.5 so a normal distribution of attendances might look like this: N Lots of people will attend close to 15 sessions but a few will attend as little as 6 and some as many as 24 (95% of people are within this range – anyone know why?)

Second Order Monte Carlo Probabilities and utilities were varied on a beta distribution Costs were varied on a gamma distribution (except unit cost of treatment which was fixed) Due to uncertainty around underlying prevalence estimates for treatment referral the s.e. was set equal to the mean Random numbers are generated for all parameters simultaneously and the resulting values, sampled from their distribution are used as the parameters for that ‘run’ of the model This re-sampling process is repeated 1000 times in order to obtain a distribution of results Let’s have a look at the Monte Carlo in action! Demonstration Now we have 1000 different ICERs to work with

SE quadrant – dominant, NW quadrant Dominated, NE and SW depend on threshold ICER (willingness-to-pay)

Results of PSA TypeOptionICER (£/QALY) Prob Cost effective at £20k/QALYEVPI £20k/QALY (WSx) PSAAlc Male/Alc Male Treat£2, £64, PSAAlc Female/Alc Female Treat£5, £73, PSA Alc Male/Alc Male Treat (Disc 6/1.5)£2, £62, PSA Alc Female/Alc Female Treat(Disc 6/1.5)£4, £74, In the mean case, the intervention remains cost effective in both men and women and is not sensitive to changes in discount rate The probability that the intervention is cost effective is about 80% for men and 70% for women (great similarity between the costs of states for women led to greater uncertainty)